calcium acetate is used as an oral phosphate binder to control hyperphosphatemia in patients with chronic renal failure. compared to calcium carbonate, control of hyperphosphatemia can be achieved at lower calcium administration with calcium acetate which likely reduces the risk of hypercalcemia. in this study, various formulations of calcium acetate tablets were prepared and their disintegrati...

Increased cardiovascular morbidity and mortality has been associated with the hyperphosphatemia seen in patients with end-stage chronic kidney disease (CKD). Oral phosphate binders are prescribed in these patients to prevent intestinal absorption of dietary phosphate and reduce serum phosphate. In prospective observational cohorts they have shown to decrease all-cause and cardiovascular mortali...

Treatment of hyperphosphataemia consists of dietary phosphorus restriction and/or dialysis and phosphate binders. Almost all dialysis patients require phosphate binders (calcium acetate, calcium carbonate, aluminium hydroxide). The use of calcium-based phosphate binders can result in chronic calcium overload, hypercalcemia and soft tissue calcification. Hypercalcemia is particularly common in p...

Phosphate binders are prescribed to chronic kidney disease (CKD) patients based on associations of serum phosphate concentrations with mortality and calcification, experimental evidence for direct calcifying effects of phosphate on vascular smooth muscle tissue and the central importance of phosphate retention in CKD-mineral and bone disorder (CKD-MBD). Current knowledge regarding phosphate met...

BACKGROUND Vascular calcification is a major contributing factor to mortality in end stage renal disease (ESRD). Despite the efficacy of phosphate binders to improve hyperphosphatemia, data on vascular calcification are less clear. There seems to be a difference in attenuation or delay in progression between different binders. In this in vitro experiment we tested whether phosphate binders coul...

Cardiovascular mortality is the leading cause of death in the uremic patient. Hyperphosphatemia is considered an independent risk factor associated with cardiovascular morbidity and mortality in dialysis patients. As phosphate control is not efficient with diet or dialysis, phosphate binders are commonly prescribed in patients with chronic renal failure. Aluminum salts, the first phosphate bind...

10.1586/14750708.2.6.823 © 2 Sevelamer hydrochloride is a nonabsorbed, calciumand metal-free phosphate binder, used to bind phosphate and prevent phosphate accumulation in patients with kidney failure. Sevelamer hydrochloride has been an important alternative to calcium-based phosphate binders, because calcium-based binders result in increased gastrointestinal calcium absorption and a positive ...

Phosphate control is still a great challenge in chronic kidney disease (CKD), and in spite of the great improvements in dialysis techniques, achievement of the goals for mineral metabolism control is still far from ideal. Aluminum hydroxide has been largely abandoned due to the high risk of aluminum toxicity, while the use of calcium-based phosphate binders may cause hypercalcemia, overzealous ...